Travere Therapeutics, Inc.
TVTX
$42.84
-$0.67-1.54%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -21.42M | -25.55M | -88.54M | -169.06M | -226.71M |
| Total Depreciation and Amortization | 73.15M | 60.74M | 54.70M | 50.15M | 46.48M |
| Total Amortization of Deferred Charges | 1.64M | 1.64M | 1.73M | 1.73M | 1.73M |
| Total Other Non-Cash Items | 21.66M | 14.94M | 32.77M | 30.41M | 101.61M |
| Change in Net Operating Assets | -35.42M | -14.00M | -59.26M | -28.67M | -83.77M |
| Cash from Operations | 39.61M | 37.78M | -58.61M | -115.44M | -160.66M |
| Capital Expenditure | 0.00 | 0.00 | -293.00K | -153.00K | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 8.15M | 27.89M | 52.72M | 12.11M | 35.72M |
| Cash from Investing | 8.15M | 27.89M | 52.42M | 11.96M | 35.72M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -68.90M | -68.90M | -68.90M | -- | -- |
| Issuance of Common Stock | 38.02M | 37.54M | 149.98M | 146.46M | 145.77M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.10M | -2.10M | -2.10M | -2.10M | -2.10M |
| Cash from Financing | -32.98M | -33.47M | 78.97M | 144.36M | 143.67M |
| Foreign Exchange rate Adjustments | 1.68M | 2.29M | 1.74M | 1.99M | -72.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 16.47M | 34.50M | 74.52M | 42.86M | 18.65M |